The reality is staggering. One in four dogs will develop cancer in their lifetime. Cancer is the leading cause of death in dogs over the age of two. It’s often discovered in late stages of the disease when treatment is difficult. Families of these pets are urgently looking for new and better options that not only prolong their companion’s life, but also improve quality of life. ELIAS Animal Health is elevating the hope of veterinarians and pet owners alike by changing the way cancer is fundamentally treated.
Cancer Immunotherapy. Personalized
Our approach is profoundly simple: Every canine patient is unique. Every cancer is unique. To ultimately win against this devastating killer, cancer therapy itself must also be unique. ELIAS Cancer Immunotherapy (ECI™) harnesses the power of the dog’s own immune system to eliminate the cancer.
Killer T cells. Activated.
The complexity of cancer itself makes the development and delivery of effective treatments a steep challenge. Research has shown that ex vivo activated T cells have the machinery to effectively kill cancer cells, including cancer stem cells. ELIAS Cancer Immunotherapy utilizes adoptive cell therapy to deliver an army of activated T cells.
Two Methods. Combined.
ELIAS Animal Health has developed a unique treatment protocol that vaccinates the dog with its own cancer cells to produce an immune response. Personalized T cells are then safely obtained from the patient through apheresis and then “super charged” to produce a large population of killer T cells that are reinfused into the patient to kill the cancer.
ELIAS Cancer Immunotherapy (ECI™) is significantly less toxic than traditional radiotherapy and chemotherapy. ECI could be used to treat every type of cancer, regardless of stage at diagnosis. ELIAS is taking cancer treatment to new heights.
Clinical trials. Initiated.
To meet the need for safer and more effective treatments for canine cancer, ELIAS Animal Health
is conducting a clinical trial of its cancer treatment (Canine-OST-1), an immunotherapy for canine osteosarcoma. This study is ongoing at the University of Missouri, College of Veterinary Medicine.
Another study is pending at Kansas State University, College of Veterinary Medicine.
This study will be for patients with B cell lymphoma.
Additional trials for other cancer types are in development.